PHARMACYTE BIOTECH, INC. Payments of Stock Issuance Costs
PHARMACYTE BIOTECH, INC. (PMCB) reported Payments of Stock Issuance Costs of $2.26 million for the 3-month period ending 2023-07-31, per its 10-Q filed 2023-09-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-09-18
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for the quarter ending 2023-07-31 was $2.26M.
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for the quarter ending 2022-07-31 was $0.00.
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for the quarter ending 2020-10-31 was $278.15K, a 1035.31% increase year-over-year.
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for the quarter ending 2020-07-31 was $198.15K, a 183.07% increase year-over-year.
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for fiscal 2019 was $175.00K, a 0.00% change from fiscal 2018.
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for fiscal 2018 was $175.00K, a 14.94% increase from fiscal 2017.
- PHARMACYTE BIOTECH, INC. payments of stock issuance costs for fiscal 2017 was $152.25K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 3 month as first filed | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2023-07-31 | $2.26M 10-Q · filed 2023-09-18 | ||||
| 2022-07-31 | $0.00 10-Q · filed 2023-09-18 | ||||
| 2020-10-31 | $278.15K 10-Q · filed 2021-03-12 | $476.30K derived: sum of 2 quarters · filed 2021-03-12 | |||
| 2020-07-31 | $198.15K 10-Q · filed 2021-03-12 | $194.15K 10-Q · filed 2020-09-11 | |||
| 2019-10-31 | $24.50K 10-Q · filed 2021-03-12 | $94.50K derived: sum of 2 quarters · filed 2021-03-12 | |||
| 2019-07-31 | $70.00K 10-Q · filed 2021-03-12 | $42.00K 10-Q · filed 2019-09-13 | |||
| 2019-04-30 | $175.00K 10-K · filed 2019-08-13 | ||||
| 2019-01-31 | $35.00K 10-Q · filed 2020-03-13 | $35.00K derived: sum of 2 quarters · filed 2020-03-13 | $140.00K derived: sum of 3 quarters · filed 2020-03-13 | ||
| 2018-10-31 | $0.00 10-Q · filed 2019-12-23 | $105.00K derived: sum of 2 quarters · filed 2020-03-13 | |||
| 2018-07-31 | $105.00K 10-Q · filed 2020-03-13 | ||||
| 2018-04-30 | $175.00K 10-K · filed 2019-08-13 | ||||
| 2017-07-31 | $70.00K 10-Q · filed 2019-03-14 | ||||
| 2017-04-30 | $152.25K 10-K · filed 2018-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |